“Where does it state that Al Mann will be on CNBC Monday on "Squawk On The Stret"?”
And speaking of MannKind, Rodman & Renshaw initiated coverage of MNKD today with an "Outperform" rating and $14 price target. Pfizer and Nektar Therapeutics threw in the towel on Exubera. LLY and NVO soonafter followed suit on their experimental inhalables. But Alfred Mann refused to give up. And now his product called "Afresa" is in front of the FDA. R&R headlines its research note, "All inhaled insulins are not created equal & why Afresa is not another Exubera." R&R makes a market in MNKD.
Mr. Mann will be one of our live guests on Monday.